LAUSR

after coronavirus-2). A recent systematic review using 57 studies with 250,351 survivors of COVID-19 shows that the median propor- tion of COVID-19 survivors at least 1 PASC (post-acute sequelae of COVID-19) 54% at 1 month (short-term), at 2 – 5 months (intermediate-term), and 54% at 6 or more months (long-term) The most common sequelae neurologic headaches, de fi cits, dif fi culty concentrating, cognitive impairment), (i.e., depression, anxiety, sleep disorders), abnormal-ities (i.e., dyspnea, increased oxygen requirement, pulmonary diffusion abnormalities, chest imaging abnormal-ities), and functional mobility impairment (i.e., impairment in general functioning, mobility decline, reduced exercise toler-ance). there are no therapeutic drugs for long-term symptoms in survivors of COVID-19.